Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.
复制标题
实体器官移植、HIV或B/C型肝炎感染患者的抗PD-1/PD-L1免疫治疗。
DOI：
10.1016/j.ejca.2018.09.017
复制
发表时间：
2018-11
影响因子：
8.4
通讯作者：
Menzies, Alexander M.
中科院分区：
文献类型：
--
作者：
Tio, Martin;Rai, Rajat;Ezeoke, Ogochukwu M.;McQuade, Jennifer L.;Zimmer, Lisa;Khoo, Chloe;Park, John J.;Spain, Lavinia;Turajlic, Samra;Ardolino, Luke;Yip, Desmond;Goldinger, Simone M.;Cohen, Justine V.;Millward, Michael;Atkinson, Victoria;Kane, Alisa Y.;Ascierto, Paolo A.;Garbe, Claus;Gutzmer, Ralf;Johnson, Douglas B.;Rizvi, Hira A.;Joshua, Anthony M.;Hellmann, Matthew D.;Long, Georgina V.;Menzies, Alexander M.
Anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immunotherapy is now routinely used to treat several cancers. Clinical trials have excluded several populations, including patients with solid organ transplant, HIV infection and hepatitis B/C infection. We examined the safety outcomes of these populations treated with anti-PD-1/PD-L1 treatment in a multicentre retrospective study. Patients from 16 centres with advanced cancer and solid organ transplant, HIV infection or hepatitis B/C infection were included. Demographic, tumour, treatment, toxicity and outcome data were recorded. Forty-six patients were included for analysis, with a median age of 60 years, and the majority of patients diagnosed with melanoma (72%). Among six patients with solid organ transplants, two graft rejections occurred, with one resulting in death, whereas two patients achieved partial responses. There were four responses in 12 patients with HIV infection. In 14 patients with hepatitis B, there were three responses, and similarly, there were three responses in 14 patients with hepatitis C. There was no unexpected toxicity in any viral infection group or an increase in viral load. Patients with HIV or hepatitis B/C infections treated with anti-PD-1/PD-L1 immunotherapy may respond to treatment without increased toxicity. Given the risk of graft rejection in solid organ transplant patients and also the potential for response, the role of anti-PD-1/PD-L1 immunotherapy needs to be carefully considered.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
120.7
作者：
Engels, Eric A.;Pfeiffer, Ruth M.;Fraumeni, Joseph F., Jr.;Kasiske, Bertram L.;Israni, Ajay K.;Snyder, Jon J.;Wolfe, Robert A.;Goodrich, Nathan P.;Bayakly, A. Rana;Clarke, Christina A.;Copeland, Glenn;Finch, Jack L.;Fleissner, Mary Lou;Goodman, Marc T.;Kahn, Amy;Koch, Lori;Lynch, Charles F.;Madeleine, Margaret M.;Pawlish, Karen;Rao, Chandrika;Williams, Melanie A.;Castenson, David;Curry, Michael;Parsons, Ruth;Fant, Gregory;Lin, Monica
通讯作者：
Lin, Monica
影响因子：
8.4
作者：
Gutzmer, Ralf;Koop, Anika;Kaehler, Katharina C.
通讯作者：
Kaehler, Katharina C.
BMS-936558的随机，双盲，安慰剂对照的评估，一种完全人类的单克隆抗体，对慢性丙型肝炎病毒感染的患者，对程序性死亡-1（PD-1）。
影响因子：
3.7
作者：
Gardiner D;Lalezari J;Lawitz E;DiMicco M;Ghalib R;Reddy KR;Chang KM;Sulkowski M;Marro SO;Anderson J;He B;Kansra V;McPhee F;Wind-Rotolo M;Grasela D;Selby M;Korman AJ;Lowy I
通讯作者：
Lowy I
影响因子：
3.8
作者：
Lake, Adam C.
通讯作者：
Lake, Adam C.